CN1562049A - Use of oligofructose in preparing medicine for treating and preventing vaginitis - Google Patents
Use of oligofructose in preparing medicine for treating and preventing vaginitis Download PDFInfo
- Publication number
- CN1562049A CN1562049A CN 200410022223 CN200410022223A CN1562049A CN 1562049 A CN1562049 A CN 1562049A CN 200410022223 CN200410022223 CN 200410022223 CN 200410022223 A CN200410022223 A CN 200410022223A CN 1562049 A CN1562049 A CN 1562049A
- Authority
- CN
- China
- Prior art keywords
- oligofructose
- medicine
- disease
- vaginitis
- content
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003814 drug Substances 0.000 title claims abstract description 28
- 201000008100 Vaginitis Diseases 0.000 title claims abstract description 27
- 206010046914 Vaginal infection Diseases 0.000 title claims description 33
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 16
- QNTKVQQLMHZOKP-NEJDVEAASA-N (2r,3r,4s,5s,6r)-2-[(2s,3s,4s,5r)-2-[[(2r,3s,4s,5r)-2-[[(2r,3s,4s,5r)-2-[[(2r,3s,4s,5r)-3,4-dihydroxy-2,5-bis(hydroxymethyl)oxolan-2-yl]oxymethyl]-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxymethyl]-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxymethyl]- Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(O[C@@H]4[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 QNTKVQQLMHZOKP-NEJDVEAASA-N 0.000 claims description 14
- 150000002584 ketoses Chemical class 0.000 claims description 14
- 238000002360 preparation method Methods 0.000 claims description 14
- 208000007976 Ketosis Diseases 0.000 claims description 13
- QNTKVQQLMHZOKP-UHFFFAOYSA-N fructofuranosylnystose Natural products OC1C(O)C(CO)OC1(CO)OCC1(OCC2(OCC3(OC4C(C(O)C(O)C(CO)O4)O)C(C(O)C(CO)O3)O)C(C(O)C(CO)O2)O)C(O)C(O)C(CO)O1 QNTKVQQLMHZOKP-UHFFFAOYSA-N 0.000 claims description 13
- 239000000203 mixture Substances 0.000 claims description 12
- 230000002265 prevention Effects 0.000 claims description 10
- 229930091371 Fructose Natural products 0.000 claims description 7
- 239000005715 Fructose Substances 0.000 claims description 7
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 claims description 7
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 7
- 229930006000 Sucrose Natural products 0.000 claims description 6
- 239000005720 sucrose Substances 0.000 claims description 6
- 239000002994 raw material Substances 0.000 claims description 5
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 4
- 239000008103 glucose Substances 0.000 claims description 4
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims description 2
- 229940079593 drug Drugs 0.000 abstract description 4
- 208000032159 Vaginal inflammation Diseases 0.000 abstract 1
- 230000000694 effects Effects 0.000 description 26
- 208000004926 Bacterial Vaginosis Diseases 0.000 description 18
- 208000037009 Vaginitis bacterial Diseases 0.000 description 18
- 210000001215 vagina Anatomy 0.000 description 15
- 230000000968 intestinal effect Effects 0.000 description 13
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 12
- 241000186660 Lactobacillus Species 0.000 description 11
- 229940039696 lactobacillus Drugs 0.000 description 11
- 241000894006 Bacteria Species 0.000 description 9
- 206010047799 Vulvovaginitis trichomonal Diseases 0.000 description 9
- 201000010099 disease Diseases 0.000 description 9
- 241000186016 Bifidobacterium bifidum Species 0.000 description 8
- 230000000813 microbial effect Effects 0.000 description 7
- 239000000126 substance Substances 0.000 description 7
- 239000003826 tablet Substances 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- 239000002028 Biomass Substances 0.000 description 6
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Chemical compound CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 6
- 229920001542 oligosaccharide Polymers 0.000 description 6
- 150000002482 oligosaccharides Chemical class 0.000 description 6
- 235000018291 probiotics Nutrition 0.000 description 6
- 230000000844 anti-bacterial effect Effects 0.000 description 5
- 239000000843 powder Substances 0.000 description 5
- 231100000331 toxic Toxicity 0.000 description 5
- 230000002588 toxic effect Effects 0.000 description 5
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 4
- 235000011054 acetic acid Nutrition 0.000 description 4
- 230000003115 biocidal effect Effects 0.000 description 4
- 238000009395 breeding Methods 0.000 description 4
- 230000001488 breeding effect Effects 0.000 description 4
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 4
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 4
- 230000003203 everyday effect Effects 0.000 description 4
- 235000013305 food Nutrition 0.000 description 4
- 229910052500 inorganic mineral Inorganic materials 0.000 description 4
- 244000000010 microbial pathogen Species 0.000 description 4
- 239000011707 mineral Substances 0.000 description 4
- DUWWHGPELOTTOE-UHFFFAOYSA-N n-(5-chloro-2,4-dimethoxyphenyl)-3-oxobutanamide Chemical compound COC1=CC(OC)=C(NC(=O)CC(C)=O)C=C1Cl DUWWHGPELOTTOE-UHFFFAOYSA-N 0.000 description 4
- 231100000957 no side effect Toxicity 0.000 description 4
- 231100000252 nontoxic Toxicity 0.000 description 4
- 230000003000 nontoxic effect Effects 0.000 description 4
- 239000006041 probiotic Substances 0.000 description 4
- 235000019260 propionic acid Nutrition 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 150000004666 short chain fatty acids Chemical class 0.000 description 4
- 108010062877 Bacteriocins Proteins 0.000 description 3
- 239000011575 calcium Substances 0.000 description 3
- 229910052791 calcium Inorganic materials 0.000 description 3
- 238000003745 diagnosis Methods 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 235000016709 nutrition Nutrition 0.000 description 3
- 230000035764 nutrition Effects 0.000 description 3
- 244000052769 pathogen Species 0.000 description 3
- 230000001717 pathogenic effect Effects 0.000 description 3
- 238000011084 recovery Methods 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- 241000186000 Bifidobacterium Species 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- 206010010774 Constipation Diseases 0.000 description 2
- 208000036649 Dysbacteriosis Diseases 0.000 description 2
- 208000027244 Dysbiosis Diseases 0.000 description 2
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 2
- 229920001202 Inulin Polymers 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 241000607142 Salmonella Species 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 206010000496 acne Diseases 0.000 description 2
- 229910021529 ammonia Inorganic materials 0.000 description 2
- 208000007502 anemia Diseases 0.000 description 2
- 244000052616 bacterial pathogen Species 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 208000002925 dental caries Diseases 0.000 description 2
- 235000013325 dietary fiber Nutrition 0.000 description 2
- 230000007140 dysbiosis Effects 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 238000000855 fermentation Methods 0.000 description 2
- 230000004151 fermentation Effects 0.000 description 2
- 238000011010 flushing procedure Methods 0.000 description 2
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 2
- 230000035876 healing Effects 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 description 2
- 229940029339 inulin Drugs 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 210000002429 large intestine Anatomy 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 239000006210 lotion Substances 0.000 description 2
- 239000011777 magnesium Substances 0.000 description 2
- 229910052749 magnesium Inorganic materials 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000010534 mechanism of action Effects 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000000505 pernicious effect Effects 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 230000035790 physiological processes and functions Effects 0.000 description 2
- 235000013406 prebiotics Nutrition 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 230000002062 proliferating effect Effects 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 239000003053 toxin Substances 0.000 description 2
- 231100000765 toxin Toxicity 0.000 description 2
- ODEHMIGXGLNAKK-OESPXIITSA-N 6-kestotriose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@@H]1[C@@H](O)[C@H](O)[C@](CO)(O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)O1 ODEHMIGXGLNAKK-OESPXIITSA-N 0.000 description 1
- 241000589220 Acetobacter Species 0.000 description 1
- 208000002874 Acne Vulgaris Diseases 0.000 description 1
- 208000037259 Amyloid Plaque Diseases 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- RFSUNEUAIZKAJO-VRPWFDPXSA-N D-Fructose Natural products OC[C@H]1OC(O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-VRPWFDPXSA-N 0.000 description 1
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 101100117236 Drosophila melanogaster speck gene Proteins 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 208000003351 Melanosis Diseases 0.000 description 1
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- 102000004316 Oxidoreductases Human genes 0.000 description 1
- 108090000854 Oxidoreductases Proteins 0.000 description 1
- 206010067268 Post procedural infection Diseases 0.000 description 1
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 1
- 241000194019 Streptococcus mutans Species 0.000 description 1
- 102000019197 Superoxide Dismutase Human genes 0.000 description 1
- 108010012715 Superoxide dismutase Proteins 0.000 description 1
- 102000004357 Transferases Human genes 0.000 description 1
- 108090000992 Transferases Proteins 0.000 description 1
- 229930003451 Vitamin B1 Natural products 0.000 description 1
- 229930003779 Vitamin B12 Natural products 0.000 description 1
- 229930003471 Vitamin B2 Natural products 0.000 description 1
- 229930003537 Vitamin B3 Natural products 0.000 description 1
- LXNHXLLTXMVWPM-UHFFFAOYSA-N Vitamin B6 Natural products CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 206010000210 abortion Diseases 0.000 description 1
- 231100000176 abortion Toxicity 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000003712 anti-aging effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000003796 beauty Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000000711 cancerogenic effect Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 231100000357 carcinogen Toxicity 0.000 description 1
- 239000003183 carcinogenic agent Substances 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- FDJOLVPMNUYSCM-WZHZPDAFSA-L cobalt(3+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+3].N#[C-].N([C@@H]([C@]1(C)[N-]\C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C(\C)/C1=N/C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C\C1=N\C([C@H](C1(C)C)CCC(N)=O)=C/1C)[C@@H]2CC(N)=O)=C\1[C@]2(C)CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@H]1[C@@H](O)[C@@H](N2C3=CC(C)=C(C)C=C3N=C2)O[C@@H]1CO FDJOLVPMNUYSCM-WZHZPDAFSA-L 0.000 description 1
- 230000002354 daily effect Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 235000019621 digestibility Nutrition 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 239000007938 effervescent tablet Substances 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 229960000304 folic acid Drugs 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- FTSSQIKWUOOEGC-RULYVFMPSA-N fructooligosaccharide Chemical compound OC[C@H]1O[C@@](CO)(OC[C@@]2(OC[C@@]3(OC[C@@]4(OC[C@@]5(OC[C@@]6(OC[C@@]7(OC[C@@]8(OC[C@@]9(OC[C@@]%10(OC[C@@]%11(O[C@H]%12O[C@H](CO)[C@@H](O)[C@H](O)[C@H]%12O)O[C@H](CO)[C@@H](O)[C@@H]%11O)O[C@H](CO)[C@@H](O)[C@@H]%10O)O[C@H](CO)[C@@H](O)[C@@H]9O)O[C@H](CO)[C@@H](O)[C@@H]8O)O[C@H](CO)[C@@H](O)[C@@H]7O)O[C@H](CO)[C@@H](O)[C@@H]6O)O[C@H](CO)[C@@H](O)[C@@H]5O)O[C@H](CO)[C@@H](O)[C@@H]4O)O[C@H](CO)[C@@H](O)[C@@H]3O)O[C@H](CO)[C@@H](O)[C@@H]2O)[C@@H](O)[C@@H]1O FTSSQIKWUOOEGC-RULYVFMPSA-N 0.000 description 1
- 229940107187 fructooligosaccharide Drugs 0.000 description 1
- 235000013376 functional food Nutrition 0.000 description 1
- 210000003736 gastrointestinal content Anatomy 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000007952 growth promoter Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000008821 health effect Effects 0.000 description 1
- 208000007386 hepatic encephalopathy Diseases 0.000 description 1
- 235000012907 honey Nutrition 0.000 description 1
- 230000003301 hydrolyzing effect Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 description 1
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 230000037356 lipid metabolism Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 210000000214 mouth Anatomy 0.000 description 1
- DFPAKSUCGFBDDF-UHFFFAOYSA-N nicotinic acid amide Natural products NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 1
- 125000000018 nitroso group Chemical group N(=O)* 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000008855 peristalsis Effects 0.000 description 1
- RADKZDMFGJYCBB-UHFFFAOYSA-N pyridoxal hydrochloride Natural products CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 description 1
- ZUFQODAHGAHPFQ-UHFFFAOYSA-N pyridoxine hydrochloride Chemical compound Cl.CC1=NC=C(CO)C(CO)=C1O ZUFQODAHGAHPFQ-UHFFFAOYSA-N 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- KYMBYSLLVAOCFI-UHFFFAOYSA-N thiamine Chemical compound CC1=C(CCO)SCN1CC1=CN=C(C)N=C1N KYMBYSLLVAOCFI-UHFFFAOYSA-N 0.000 description 1
- 229960003495 thiamine Drugs 0.000 description 1
- 230000017105 transposition Effects 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 235000010374 vitamin B1 Nutrition 0.000 description 1
- 239000011691 vitamin B1 Substances 0.000 description 1
- 235000019163 vitamin B12 Nutrition 0.000 description 1
- 239000011715 vitamin B12 Substances 0.000 description 1
- 235000019164 vitamin B2 Nutrition 0.000 description 1
- 239000011716 vitamin B2 Substances 0.000 description 1
- 235000019160 vitamin B3 Nutrition 0.000 description 1
- 239000011708 vitamin B3 Substances 0.000 description 1
- 235000019158 vitamin B6 Nutrition 0.000 description 1
- 239000011726 vitamin B6 Substances 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
An application of oligopectose is preparing the medicines for treating and preventing various vaginal inflammations is disclosed.
Description
Technical field
The present invention relates to the purposes of oligofructose (can use any in ketose, C24H42 O21 and the Fructofuranosyl nystose, also available any two kinds or any three kinds mixture separately), particularly the purposes in pharmaceutical field.
Background technology
(Fructooligosaccharide FOS), has another name called oligofructose or oligosaccharide of kestose family to oligofructose, is the natural activity composition that is present in fruit, vegetable, the honey and other substances, good water soluble dietary fiber.Oligofructose mainly is to utilize the enzyme that has fructose transferase activity in microorganism or the plant to act on sucrose and obtain, and also has with endoinulase hydrolytic inulin (or being called inulin) to obtain.The C1 position that is the fructose of sucrose (GF) (or is described as: on the residue of fructose C1 of sucrose and C2 position with β-1 in conjunction with 1～3 molecule fructose by β-2-1 glycosidic bond, the 2-glycosidic bond connects the D-fructose of 1～3 molecule and the oligosaccharide that forms) oligosaccharide that constituted, its molecular formula is G-F-Fn, n=1～3 (wherein: F is a fructose, and G is a glucose).When n=1, be called ketose (GF2), when n=2, be called C24H42 O21 (GF3), when n=3, be called Fructofuranosyl nystose (GF4).
Oligofructose is up to the present to one of the most detailed prebiotics of the research of the health effect of human body research.Because its good mouthfeel, significant physiological function at home and abroad come into one's own day by day.In natural non-digestibility functional food, oligofructose is the typical bifidus factor that meets the prebiotics standard fully.
The mechanism of action of oligofructose mainly contained two: the first, oligofructose can not be digested by human body, can complete arrival large intestine, by the profitable strain bacillus bifidus of human body and lactobacillus selective use and rapid a large amount of propagation (bacillus bifidus quantity can be bred 10～1000 times, and lactobacillus can be bred more than 10 times).And produce short-chain fatty acid such as acetic acid, lactic acid, propanoic acid, butanoic acid etc. and reduce the intestinal pH value.A large amount of probioticss is by secretion H
2O
2Suppress the growth and breeding and the field planting of pernicious bacterias such as pathogenic bacterium and putrefaction bacteria with antibacterial substance such as bacteriocin and occupy-place field planting, competition nutrition etc., and form Mycoderma protection barrier, reduce the pathogenic bacterium transposition to enter body at intestinal wall; And low pH value not only can stimulate intestinal peristalsis promoting, accelerating intestinal contents discharges, also can work in coordination with the activity that probiotics suppresses the growth and breeding of pernicious bacteria and reduces some harmful reductase in the intestinal, reduce formation, accumulation and the absorption of carcinogen (as indole, nitroso-group ammonia etc.) and harmful metabolite (as ammonia, amine etc.) and accelerate its drainage, really play the effect of removing intestinal rubbish.The second, oligofructose is the small-molecule substance with water soluble dietary fiber characteristic, can keep the moisture of intestinal wall.In gastrointestinal tract, can reduce fat absorption with fatty the combination; Oligofructose decomposes the short-chain fatty acid produced such as propanoic acid can suppress the synthetic of cholesterol in the liver, and the conversion of glucose that acetic acid can suppress in the liver is fat.Take for a long time and can reduce serum cholesterol, improve lipid metabolism.Oligofructose and mineral calcium, magnesium, ferrum, zinc etc. can be combined into complex, are decomposed and discharge mineral at large intestine, and low simultaneously intestinal pH value helps the mineral dissolving and absorbs.In addition, a large amount of probioticss also can be by self and more excretory immune materials and antioxidant (as superoxide dismutase, SOD) and the effect of oligofructose and stimulate or improve the immunity and the oxidation resistance of body.
Studies confirm that in a large number oligofructose has following physiological function:
1, improves the anti-intestinal tract disease ability of body, effectively prevent and treat diarrhoea;
2, loosening bowel to relieve constipation prevents constipation;
3, safe toxin expelling, the liver protecting, reduction organism metabolism load: it is lasting, without any side effects that the toxin expelling effect is significantly stablized, and treats hepatic encephalopathy and prevent effects such as various chronic diseases, cancer obviously;
4, blood fat reducing: can effectively reduce the quantity of serum cholesterol, triglyceride, free fatty, have a better role for a series of cardiovascular disease such as the hypertension that causes because of blood fat height, diabetes, arteriosclerosis;
5, promote the synthetic of vitamin: bacillus bifidus and and lactobacillus can synthetic vitamin B1, B2, B3, B6, B12 and folic acid, thereby improve the human body metabolism;
6, promote mineral such as Ca, Mg, Fe to absorb: experiment confirm, oligofructose promote the absorbance of calcium to reach 70.8%.Can promote growth promoter and prevent osteoporosis;
7, prevent obesity: the calorific value of oligofructose is 1.5kcal/g following (sucrose is 4.6Kcal/g), is the functional sweetener of ideal, low heat value, low sugariness;
8, prevent dental caries: oligofructose can not can be prevented dental caries by the streptococcus mutans utilization in oral cavity;
9, beauty treatment and anti-aging effects: after taking oligofructose, can prevent acne vulgaris, black speck, freckle, comedo, senile plaque, make skin beautiful, aging slowing down.
Various vaginitiss (disease) such as bacterial vaginosis, infusorian property and colpitis mycotica are the common vaginal infection of child-bearing period women, and these vaginitiss (disease) are not only unhealthful, and are also relevant with disease and/or the postoperative infection and the abortion etc. of many department of obstetrics and gynecology.Research confirms that the main pathological change of above-mentioned vaginitis (disease) is the dysbacteriosis of vagina, and therefore recovering the normal microecology in vaginas balance of patient is treatment (healing) above-mentioned vaginitis (disease), and prevents one of key that recurs.At present all kinds vaginitis (disease) such as treatment women bacterial vaginosis, trichomonal vaginitis and colpitis mycotica if the drug main antibiotic and some have the lotion (washing liquid) of antibacterial action, but use the lotion (washing liquid) of (especially life-time service) antibiotic and these antibacterial actions, not only can make the various pathogen that cause vaginitis (disease) produce drug resistance; And abuse of antibiotics also can further aggravate intravaginal dysbacteriosis, and this is that above-mentioned clinically vaginitis (disease) patient curative effect reduces and the major reason of obstinate recurrence gradually; Main is that most antibiotic can not or not be suitable for anemia of pregnant woman and women's infant.In addition, also have in the domestic and international research minority use the lactobacillus viable bacteria as the microbial ecological agent of main component as the multiple vaginitis of Drug therapy (disease), effect and antibiotic etc are quite or better, but the viable bacteria in these active bacteria formulations is relatively more fragile, room temperature is dead easily down, holding time is short, so that the viable count and the measured result that mark on some products are not inconsistent, even can't measure, thereby its effect is a greater impact during practical application, effect instability, range of application are subjected to bigger restriction, fail to be widely used.
Summary of the invention
The object of the present invention is to provide the application of oligofructose in the medicine of preparation treatment and prevention vaginitis disease.
Oligofructose of the present invention is meant a kind of separately in these three kinds of oligofructoses (being called total oligosaccharide again) of ketose (GF2), C24H42 O21 (GF3) and Fructofuranosyl nystose (GF4), also any two or three mixture.
Being 80%～100% in the total oligofructose content of dry measure in the oligofructose raw material of the present invention, is 90%～100% in the total oligofructose content of dry measure preferably.
When oligofructose raw material of the present invention is the mixture of ketose (GF2), C24H42 O21 (GF3) and Fructofuranosyl nystose (GF4), the content of ketose (GF2) is 25～70%, the content of C24H42 O21 (GF3) is 25～70%, the content of Fructofuranosyl nystose (GF4) is 1～15%, and the content of sucrose, glucose, these three kinds of sugar of fructose is 0%～10%.
Medicine of the present invention can be made powder, piece agent, tablet, suppository, effervescent tablet, capsule, washing liquid, spray or unguentum according to a conventional method.
The mixture of a kind of or wherein any two kinds of oligosaccharide in the ketose in the oligofructose (GF2), C24H42 O21 (GF3), the Fructofuranosyl nystose or the mixture of these three kinds of oligosaccharide all can promote in the vagina and/or the probiotics lactobacillus in the intestinal and the growth and breeding of bacillus bifidus specifically, and prolific lactobacillus and bacillus bifidus can be by occupy-place field planting, competition nutrition, secretion H
2O
2With antibacterial substances such as bacteriocins and suppress in the vagina and/or the growth of pathogenic microorganism in the intestinal; Simultaneously, oligofructose can produce a large amount of short-chain fatty acid such as acetic acid, propanoic acid and butanoic acid etc. after by lactobacillus and bifidobacterium fermentation utilization, and reduced in intravaginal and the territory intestinal pH value and electromotive force (Eh), this environment all has inhibitory action to multiple vaginitis (disease) pathogenic microorganism as pathogen such as Gardner Salmonella, infusorian, mycetes.By above mechanism of action, thus little ecological recovery of vagina imbalance to normal condition.The effect that reaches treatment various vaginitiss (disease) and prevent its recurrence and/or generation.
Because oligofructose works by promoting intravital probiotics lactobacillus and bacillus bifidus in the present invention, and oligofructose itself is to human body safety non-toxic, the chemical substance that has no side effect, be used for (comprising China) processing of food for a plurality of countries, especially in infant and old people's food.Thereby the present invention also is safety non-toxic, has no side effect human body; Simultaneously, the oligofructose consumption is few, good effect, and good stability, the holding time is long, and price is low.Not only can be used for treating and preventing adult women's vaginitis (disease), and can be applicable to anemia of pregnant woman and women's infant, children and youth preferably.It is a kind of newtype drug of brand-new, the multiple vaginitis (disease) that is used to the women for preparing the treatment and prevent various physiological statuss.Find through long-term observation, the local use of long-term in daily life low dose of vagina, oral prevents the effect of various bacterial vaginosis, trichomonal vaginitis, colpitis mycotica in addition to the women of various vaginitiss of not suffering from of various physiological statuss (disease); The women who suffered from various vaginitiss (disease) to various physiological statuss can reach the effect of prevention of recurrence at treatment (healing) back life-time service, and does not see any toxic and side effects.
The specific embodiment
In order to understand essence of the present invention better, will test with the clinical observation of the mixture of ketose, C24H42 O21 and Fructofuranosyl nystose below its new purposes in pharmaceutical field will be described.Similarly, separately with above-mentioned three kinds a kind of or any two kinds all can reach same pharmacological effect, difference is the difference on amount only.
Embodiment 1: at total oligofructose content is in the mixture of 95% ketose, C24H42 O21 and Fructofuranosyl nystose, in sterilizing room, add heavily steam on a small quantity sterilized water moistening after, tabletting, the tablet that contains oligofructose (in total oligofructose) amount 0.2g in making every is standby.
Embodiment 2: they with total oligofructose content the mixture of 95% ketose, C24H42 O21 and Fructofuranosyl nystose, and packing, it is standby to make every bag of weight 11g (being roughly equal to 10.45g in total oligofructose).
Observe example 1: the local clinical observation example of using of the vagina of the tablet that total oligofructose content is 0.2g in every
According to a complete set of patient's 28 examples made a definite diagnosis of checking of clinical symptoms and leucorrhea, bacterial vaginosis 8 examples wherein, colpitis mycotica 10 examples, trichomonal vaginitis 10 examples.The patient puts into the vagina deep with tablet a slice oligofructose tablet of embodiment 1 preparation evening every day after the vagina part is with eliminating cold for resuscitation water flushing 2～4 times.Treat check after 21 days.The results are shown in following table 1, table 2.Do not see any toxic and side effects during the treatment.
Table 1 bacterial vaginosis/colpitis mycotica/trichomonal vaginitis patient treatment effect
The therapeutic effect total effective rate
Grouping adds up to
(%) cured in invalid improvement
Bacterial vaginosis 2428 75.00
Colpitis mycotica 361 10 70.00
Trichomonal vaginitis 352 10 60.00
Add up to 9 14 5 28 67.86
Microbial biomass contrast before and after table 2 bacterial vaginosis/colpitis mycotica/trichomonal vaginitis patient treatment
The microbial biomass classification
Add up to
- + ++ +++ ++++
Bacterial vaginosis takes medicine preceding 000358
(you count the Gardner by the bacterium) back 223108 of taking medicine
Colpitis mycotica takes medicine preceding 03421 10
(mold count) takes medicine back 15310 10
Trichomonal vaginitis takes medicine preceding 02530 10
(infusorian counting) takes medicine back 24400 10
Observe example 2: the vagina of the tablet that total oligofructose content is 0.2g in every is local to be used and the oral clinical observation example of 11g pockaged powder
According to a complete set of patient's 20 examples made a definite diagnosis of checking of clinical symptoms and leucorrhea, bacterial vaginosis 10 examples wherein, colpitis mycotica 10 examples.The patient puts into the vagina deep with tablet a slice of embodiment 1 preparation evening every day after the vagina part is with eliminating cold for resuscitation water flushing 2～3 times.Simultaneously the patient that the powder of every bag of weight 11g of embodiment 2 preparations is dissolved in the eliminating cold for resuscitation water back is oral, each one bag, every day secondary.Treatment check after 21 days continuously.The results are shown in Table 3, table 4.Do not see any toxic and side effects during the treatment.
Table 3 bacterial vaginosis/colpitis mycotica patient treatment effect
The therapeutic effect total effective rate
Grouping adds up to (%)
Bacterial vaginosis 154 10 90.00
Colpitis mycotica 262 10 80.00
Add up to 3 11 6 20 85.00
Microbial biomass contrast before and after table 4 bacterial vaginosis/colpitis mycotica/trichomonal vaginitis patient treatment
The microbial biomass classification
Add up to
- + ++ +++ ++++
Bacterial vaginosis takes medicine preceding 00064 10
(you count the Gardner by the bacterium) back 72100 10 of taking medicine
Colpitis mycotica takes medicine preceding 02422 10
(mold count) takes medicine back 61210 10
The clinical observation example that embodiment 3:11g pockaged powder is oral
By a complete set of asymptomatic bacterial vaginosis patient 4 examples of making a definite diagnosis of checking of leucorrhea, it is oral that the patient is dissolved in the eliminating cold for resuscitation water back with the powder of every bag of weight 11g of embodiment 2 preparations in clinical health check-up, each one bag, every day secondary.Treatment check after 28 days continuously.3 people leucorrhea check that every index recovery is normal, clinical cure, and 1 people takes a turn for the better.The results are shown in Table 5, table 6.Do not see any toxic and side effects during the treatment.
Table 5 bacterial vaginosis/colpitis mycotica patient treatment effect
The therapeutic effect total effective rate
Grouping adds up to
(%) cured in invalid improvement
Bacterial vaginosis 0134 100
Microbial biomass contrast before and after table 6 bacterial vaginosis/colpitis mycotica/trichomonal vaginitis patient treatment
The microbial biomass classification
Add up to
- + ++
Bacterial vaginosis takes medicine preceding 0134
(you count the Gardner by the bacterium) back 3104 of taking medicine
From above result, can draw and the invention has the advantages that:
(1) the present invention has excavated new medical application to known oligofructose, has opened up a new application.
(2) oligofructose of the present invention itself is to human body safety non-toxic, the chemical substance that has no side effect, be used for (comprising China) processing of food for a plurality of countries, especially in infant and old people's food, thereby the present invention also is safety non-toxic, has no side effect human body, in clinical observation of the present invention, never see any toxic and side effects, and pharmacological action is strong, is indicating well prospect in medicine.
(3) oligofructose consumption of the present invention is few, good effect, and good stability, the holding time is long, and price is low.Can make various dosage forms according to a conventional method, preparation technology is simply ripe.
(4) medicine that is mixed with of material of the present invention has and significantly promotes in the vagina specifically and/or the probiotics lactobacillus in the intestinal and the growth and breeding of bacillus bifidus, and prolific lactobacillus and bacillus bifidus can be by occupy-place field planting, competition nutrition, secrete H
2O
2With antibacterial substances such as bacteriocins and suppress in the vagina and/or the growth of pathogenic microorganism in the intestinal; Simultaneously, oligofructose can produce a large amount of short-chain fatty acid such as acetic acid, propanoic acid and butanoic acid etc. after by lactobacillus and bifidobacterium fermentation utilization, and reduced in intravaginal and/or the intestinal pH value and electromotive force (Eh), this environment all has inhibitory action to multiple vaginitis (disease) pathogenic microorganism as pathogen such as Gardner Salmonella, infusorian, mycetes.Thereby little ecological recovery of vagina imbalance to normal condition.The effect that reaches treatment various vaginitiss (disease) and prevent its recurrence and/or generation.
The above, it only is preferred embodiment of the present invention, be not that the present invention is done any pro forma restriction, any technical solution of the present invention content that do not break away from,, all still belong in the scope of technical solution of the present invention any simple modification, equivalent variations and modification that above embodiment did according to technical spirit of the present invention.
Claims (7)
1, the application of oligofructose in preparation treatment and prevention vaginitis medicine.
2, the application of oligofructose as claimed in claim 1 in the medicine of preparation treatment and prevention vaginitis disease, wherein oligofructose is a kind of in ketose, C24H42 O21 and the Fructofuranosyl nystose.
3, the application of oligofructose as claimed in claim 1 in the medicine of preparation treatment and prevention vaginitis disease, wherein oligofructose is any two kinds mixture in ketose, C24H42 O21 and the Fructofuranosyl nystose.
4, the application of oligofructose as claimed in claim 1 in the medicine of preparation treatment and prevention vaginitis disease, wherein oligofructose is the mixture of ketose, C24H42 O21 and Fructofuranosyl nystose.
5,, be 80%～100% in the total oligofructose content of dry measure in the oligofructose raw material wherein as the application of the described oligofructose of claim 1-4 in the medicine of preparation treatment and prevention vaginitis disease.
6, the application of oligofructose as claimed in claim 5 in the medicine of preparation treatment and prevention vaginitis disease is 90%～100% in the total oligofructose content of dry measure in the oligofructose raw material wherein.
7, the application of oligofructose as claimed in claim 4 in the medicine of preparation treatment and prevention vaginitis disease, wherein the content of ketose is 25～70% in the oligofructose raw material, the content of C24H42 O21 is 25～70%, the content of Fructofuranosyl nystose is 1～15%, and the content of sucrose, glucose, these three kinds of sugar of fructose is 0%～10%.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200410022223 CN1562049A (en) | 2004-04-02 | 2004-04-02 | Use of oligofructose in preparing medicine for treating and preventing vaginitis |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200410022223 CN1562049A (en) | 2004-04-02 | 2004-04-02 | Use of oligofructose in preparing medicine for treating and preventing vaginitis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN1562049A true CN1562049A (en) | 2005-01-12 |
Family
ID=34479978
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 200410022223 Pending CN1562049A (en) | 2004-04-02 | 2004-04-02 | Use of oligofructose in preparing medicine for treating and preventing vaginitis |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1562049A (en) |
Cited By (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2009023997A1 (en) * | 2007-08-23 | 2009-02-26 | Zhiqiang Feng | A flavoring sugar |
| CN103110665A (en) * | 2013-01-24 | 2013-05-22 | 量子高科(中国)生物股份有限公司 | Composition for maintaining genital tract micro-ecological barrier and application thereof |
| CN103316023A (en) * | 2013-06-28 | 2013-09-25 | 广州丹奇日用化工厂有限公司 | Novel lotion for females |
| CN103315205A (en) * | 2006-03-10 | 2013-09-25 | 纽崔西亚公司 | Use of non-digestable sacharides for giving an infant the best start after birth |
| CN101677980B (en) * | 2007-03-30 | 2013-10-23 | 莱克瑞股份公司 | Application of lactic acid oligomer in preparation of medicine for treating gynecological diseases |
| CN104274384A (en) * | 2014-09-05 | 2015-01-14 | 拉芳家化股份有限公司 | Body perfumed shower gel containing biological bacteriostatic agent |
| EP3355894B1 (en) | 2015-09-29 | 2024-04-24 | Kimberly-Clark Worldwide, Inc. | Composition comprising sugar for maintaining lactobacillus dominance in the urogenital area |
| US12419898B2 (en) | 2015-09-29 | 2025-09-23 | Kimberly-Clark Worldwide, Inc. | Synergistic composition for maintenance of healthy balance of microflora |
-
2004
- 2004-04-02 CN CN 200410022223 patent/CN1562049A/en active Pending
Cited By (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103315205A (en) * | 2006-03-10 | 2013-09-25 | 纽崔西亚公司 | Use of non-digestable sacharides for giving an infant the best start after birth |
| CN101677980B (en) * | 2007-03-30 | 2013-10-23 | 莱克瑞股份公司 | Application of lactic acid oligomer in preparation of medicine for treating gynecological diseases |
| WO2009023997A1 (en) * | 2007-08-23 | 2009-02-26 | Zhiqiang Feng | A flavoring sugar |
| CN103110665A (en) * | 2013-01-24 | 2013-05-22 | 量子高科(中国)生物股份有限公司 | Composition for maintaining genital tract micro-ecological barrier and application thereof |
| CN103110665B (en) * | 2013-01-24 | 2015-12-02 | 量子高科(中国)生物股份有限公司 | A kind of compositions and application thereof safeguarding genital tract micro-ecological barrier |
| CN103316023A (en) * | 2013-06-28 | 2013-09-25 | 广州丹奇日用化工厂有限公司 | Novel lotion for females |
| CN103316023B (en) * | 2013-06-28 | 2015-07-01 | 广州丹奇日用化工厂有限公司 | Novel lotion for females |
| CN104274384A (en) * | 2014-09-05 | 2015-01-14 | 拉芳家化股份有限公司 | Body perfumed shower gel containing biological bacteriostatic agent |
| EP3355894B1 (en) | 2015-09-29 | 2024-04-24 | Kimberly-Clark Worldwide, Inc. | Composition comprising sugar for maintaining lactobacillus dominance in the urogenital area |
| US12419898B2 (en) | 2015-09-29 | 2025-09-23 | Kimberly-Clark Worldwide, Inc. | Synergistic composition for maintenance of healthy balance of microflora |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2473347C1 (en) | Prebiotic composition for normalising body microflora | |
| CN1211189A (en) | Urogenital and intestinal disorder compositions comprising a substrance derived from plant species of the ericaceae family and a lactic acid bacteria growth factor | |
| CN1663573A (en) | A stable and safe microecological formulation, its preparation and usage | |
| CN103393713B (en) | The application in the medicine of preparation treatment constipation of hyaluronic acid and salt thereof | |
| CN107455744A (en) | A kind of fementative composition ferment and preparation method thereof in vivo | |
| CN107495383A (en) | A laxative compound prebiotic and its preparation method and application | |
| CN112544920A (en) | Composition for improving constipation and preparation method thereof | |
| CN102132869B (en) | Health-care product for relieving alcohol and preventing getting drunk | |
| CN102258540A (en) | Application of probiotic factor and lactobacillus mixture to preventing and treating vaginitis | |
| CN111920753A (en) | Preparation for resisting helicobacter pylori and relieving gingivitis and application thereof | |
| CN109315769A (en) | It is a kind of for improving the composition and preparation method thereof of human body enteral environment | |
| CN107647234A (en) | A kind of Ms probiotics solid beverage | |
| CN102861108B (en) | Pharmaceutical composition for treating constipation and application thereof | |
| CN116549494B (en) | Beta-1, 3/alpha-1, 3-glucan compound composition with bowel relaxing function and preparation method and application thereof | |
| CN1562049A (en) | Use of oligofructose in preparing medicine for treating and preventing vaginitis | |
| CN105535580A (en) | A biological agent for improving human body intestinal floras and a preparing method thereof | |
| CN102524649A (en) | Xylo-oligosaccharide fruit polysaccharide tablets | |
| CN115297878A (en) | Compositions for enhancing urolithin production in human subjects | |
| CN101450074B (en) | Composition capable of greatly improving gastrointestinal tract function and preventing and treating astriction | |
| CN114145460A (en) | Lactic acid bacteria, composition containing same and application | |
| CN110538218A (en) | Composition for treating mastitis | |
| CN104824511A (en) | Prebiotics composition | |
| CN101199492A (en) | Application of oligomerization xylose and xylito in coating slice coating | |
| CN1102394C (en) | Health care product containing lactein and its preparing method | |
| CN107837274A (en) | A kind of purposes of diet fiber composition |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |